Skip to main content
TipRanks
Go Ultimate75% OFF

BioNTech SE (BNTX) AI Stock Analysis

4,933 Followers
BNTX

BioNTech SE

(NASDAQ:BNTX)

Select Model
Rating:55Neutral
Price Target:$89.00â–²(4.88% Upside)
Action:reiterated
Date:11/04/26

BNTX scores mid-range primarily because a very strong, low-debt balance sheet and constructive pipeline/guidance commentary are offset by a sharply weaker earnings profile (structural revenue downshift, ongoing losses) and pressured TTM cash flow. Technicals also weigh on the score, with the stock below key moving averages and negative MACD, while valuation is difficult to support due to negative earnings and no stated dividend yield.

Positive Factors
Balance Sheet StrengthBioNTech’s substantial liquidity and very low leverage provide durable flexibility to fund late-stage trials, pursue partnerships, absorb development setbacks, and sustain operations while revenues transition beyond COVID-19 products. This reduces financing pressure during a costly commercialization buildout.
Negative Factors
Structural Revenue DeclineThe sharp retreat from pandemic-era revenue reflects BioNTech’s continuing dependence on COVID-19 demand and the difficult transition toward oncology products. Lower recurring revenue reduces operating leverage and makes future profitability more dependent on successful launches or partnership milestones.

BioNTech SE Key Performance Indicators (KPIs)

Revenue by SegmentShows how much revenue comes from each business line—vaccine sales and partner arrangements (notably revenues tied to the COVID-19 vaccine and Pfizer collaboration), oncology and other therapeutic programs, licensing and collaboration income, and services. Helps investors see whether growth depends on a single product or partner, how much revenue is recurring versus one‑time, and which segments offer sustainable long‑term upside or face regulatory, competitive, or demand risks.

€0.00€2.00B€4.00B€6.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

BioNTech has moved from a steady, vaccine‑led revenue base to a lumpy, milestone‑and collaboration‑driven profile: COVID vaccine demand is clearly soft and management flags H2 concentration centered on a EUR 613m BMS payment, making near‑term results heavily timing‑dependent. That increases execution and phasing risk even as clinical programs advance and the company sits on a large cash cushion; investors should monitor milestone recognition timing, vaccine demand trends, and rising SG&A/one‑time charges that can compress margins despite strong cash reserves.

Data provided by:The Fly

BioNTech SE (BNTX) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%BNTX-12.49%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$21.04B
Dividend Yield
―
Average Volume (3M)
1.25M
Price to Earnings (P/E)
-13.0
Beta (1Y)
1.01
Revenue Growth
-20.72%
EPS Growth
-160.57%
Country
US
Employees
7,807
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

BioNTech SE Business Overview & Revenue Model

Company Description

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which fe...

How the Company Makes Money

BioNTech makes money primarily through (1) commercialization-related income from its COVID-19 vaccine collaboration with Pfizer and (2) collaboration, licensing, and research revenues from partnerships supporting its broader mRNA and immuno-oncology...

BioNTech SE Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:-3.05%|Next Earnings Date:May 12, 2020
Earnings Call SentimentPositive

The call was broadly optimistic, supported by strong gotistobart survival data, encouraging pumitamig combination results, a growing late-stage pipeline, a substantial cash balance, and a raised revenue-guidance midpoint. However, the company also reported lower COVID-19-related revenue, higher R&D and SG&A expenses, discontinuation of the colorectal cancer trial, a missed progression-free survival endpoint for BNT113, and limitations and safety concerns around T-Pam. The highlights significantly outweighed the lowlights, although several clinical programs remain subject to upcoming readouts and development decisions.

Positive Updates

Gotistobart Nearly Doubled Median Overall Survival
In the non-pivotal stage of the global phase III trial in metastatic squamous non-small cell lung cancer after prior checkpoint inhibitor treatment, gotistobart produced median overall survival of 18.5 months versus 10 months with docetaxel, with a hazard ratio of 0.56 and a 44% reduction in the risk of death compared with chemotherapy. The pivotal stage is ongoing, with an interim analysis anticipated before year-end.

Negative Updates

Third-Quarter Revenue Decline
Third-quarter 2026 revenue was EUR 1.3 billion versus EUR 1.5 billion in the prior-year quarter. The decline mainly reflected anticipated lower market demand for BioNTech's COVID-19 vaccine.

Company Guidance

BioNTech raised its full year 2026 revenue guidance to EUR 1.7 billion to EUR 1.9 billion, while maintaining adjusted R&D expense guidance of EUR 2 billion to EUR 2.3 billion and adjusted SG&A expense guidance of EUR 700 million to EUR 800 million; it expects the first interim analysis for gotistobart in squamous non-small cell lung cancer before year-end, a second one next year, first trials for pumitamig and Alpha-D novel combinations to begin in 2027, first-line TNBC in China data in 2027, ROSETTA Lung-02 and ROSETTA Lung-01 around 2029, and readouts for RCC, CRC, HCC, and the other studies thereafter, while it has seven global pivotal studies ongoing by end of this year and remains on track to become a diversified multi-product company by 2030.

BioNTech SE Financial Statement Overview

Summary

Fundamentals are mixed: the balance sheet is a major strength (very low leverage and substantial equity/cash flexibility), but the income statement is weak with a structural revenue downshift and sustained losses. Cash flow is also pressured with negative operating and free cash flow in TTM, despite a rebound in 2025, raising sustainability concerns.

Income Statement

34Negative

Balance Sheet

82Very Positive

Cash Flow

41Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.41B2.76B2.75B3.82B17.31B18.98B
Gross Profit1.69B2.14B2.21B3.22B14.32B16.07B
EBITDA-527.76M-628.00M-367.10M1.38B13.10B15.00B
Net Income-1.48B-1.09B-665.30M930.30M9.43B10.29B
Balance Sheet
Total Assets20.17B21.98B22.53B23.01B23.28B15.83B
Cash, Cash Equivalents and Short-Term Investments10.20B14.83B16.78B16.55B14.06B2.07B
Total Debt359.80M267.29M254.20M219.10M212.20M301.50M
Total Liabilities2.46B2.76B3.12B2.76B3.22B3.94B
Stockholders Equity17.71B19.22B19.41B20.25B20.06B11.89B
Cash Flow
Free Cash Flow-456.19M269.81M-244.60M4.67B13.21B735.70M
Operating Cash Flow-247.56M438.00M207.70M5.37B13.58B889.70M
Investing Cash Flow771.26M-2.37B-2.08B-6.95B-35.30M-566.10M
Financing Cash Flow-330.69M-50.81M-45.90M-778.60M-1.42B94.20M

BioNTech SE Technical Analysis

Technical Analysis SentimentNegative
Last Price84.86

Price Trends

50DMA92.43Negative
100DMA94.54Negative
200DMA95.48Negative

Market Momentum

MACD-1.97Negative
RSI38.88Neutral
STOCH14.23Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Negative. The current price of 84.86 is below the 20-day moving average (MA) of 87.50, below the 50-day MA of 92.43, and below the 200-day MA of 95.48, indicating a bearish trend. The MACD of -1.97 indicates Negative momentum. The RSI at 38.88 is Neutral, neither overbought nor oversold. The STOCH value of 14.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNTX.

BioNTech SE Risk Analysis

BioNTech SE disclosed 1 risk factors in its most recent earnings report. BioNTech SE reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.Issues in the development and use of AI, combined with an uncertain regulatory environment, may result in reputational harm, liability or other adverse consequences to our business.Q4, 2023
2.Government policies, including relating to manufacturing or export controls, and negative public perception regarding vaccines and mRNA-based therapeutics could severely and adversely impact the manufacturing and sales of our COVID-19 vaccine and other product candidates we may develop, if approved.Q4, 2023
3.If we are a "passive foreign investment company" for U.S. federal income tax purposes, there may be adverse U.S. federal income tax consequences to U.S. investors.Q4, 2023

BioNTech SE Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BNTX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
UTHRUTHR85Outperform$24.88B20.4319.18%―1.89%0.33%
INCYINCY73Outperform$24.27B57.017.11%―24.88%-65.67%
GMABGMAB63Neutral$30.87B43.4112.26%―19.61%-50.40%
MRNAMRNA60Neutral$83.68B-29.14-37.62%―13.13%12.35%
ROIVROIV57Neutral$28.05B-79.89-8.08%―102.09%9.46%
BNTXBNTX55Neutral$21.04B-12.97-8.09%―-20.72%-160.57%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%250%500%750%1000%BNTXINCYUTHRGMABMRNAROIVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BNTX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BNTXBiontech Se Sponsored Adr84.86-16.57-16.34%
INCYIncyte119.0917.7717.54%
UTHRUnited Therapeutics Corp.584.10107.5622.57%
GMABGenmab (Otc)51.9621.3969.97%
MRNAModerna206.80182.62755.25%
ROIVRoivant Sciences Ltd.38.7118.3790.31%

BioNTech SE Corporate Events

BioNTech Reports Third-Quarter Results, Advances Oncology Pipeline

Nov 3, 2026

BioNTech SE is a biotechnology company focused on mRNA-based vaccines and immunotherapies, with a growing emphasis on oncology, antibody-drug conjugates and infectious-disease products. Its commercial portfolio includes COVID-19 vaccines, while its d...

BioNTech Reports Third-Quarter and Nine-Month 2026 Results

Nov 3, 2026

BioNTech SE is a biotechnology company developing mRNA-based medicines, immunotherapies and vaccines, with a market focus on oncology and infectious diseases. Its platform-driven approach supports the company’s positioning across oncology and infecti...

BioNTech and Bristol Myers Squibb Post Strong Phase 2 Pumitamig Data in Second‑Line Lung Cancer

Oct 26, 2026

On October 25, 2026, BioNTech and Bristol Myers Squibb reported first data from the global Phase 2 ROSETTA Lung-107 trial of pumitamig plus docetaxel in metastatic non-small cell lung cancer after progression on immunotherapy plus chemotherapy. The c...

BioNTech and DualityBio Report Modest Phase 3 Benefit for Trastuzumab Pamirtecan in HR+/HER2‑Low Breast Cancer

Oct 26, 2026

On October 26, 2026, BioNTech and DualityBiologics reported topline results from the global Phase 3 DYNASTY‑Breast02 trial of trastuzumab pamirtecan in HR+/HER2‑low metastatic breast cancer, showing the study met its primary endpoint with a statistic...

BioNTech and Gilead Recast Phase 3 ROSETTA Trial Around ADC Combo in Triple-Negative Breast Cancer

Oct 22, 2026

BioNTech SE has entered a clinical trial collaboration and supply agreement with Gilead Sciences to evaluate pumitamig in combination with Gilead’s TROP2‑directed antibody‑drug conjugate sacituzumab govitecan as first‑line therapy for patients with l...

BioNTech Showcases Broad Late-Stage Oncology Data and Novel Combinations at ESMO 2026

Oct 19, 2026

On October 19, 2026, BioNTech announced it will showcase new clinical data from its late-stage oncology pipeline via 16 abstracts at the ESMO 2026 Congress in Madrid from October 23–27, 2026. The presentations span ten tumor types, underlining the br...

BioNTech Presses Ahead With BNT113 Cancer Trial After Initial Endpoint Miss

Oct 13, 2026

On October 13, 2026, BioNTech reported first topline data from its AHEAD‑MERIT Phase 2/3 trial of investigational mRNA cancer immunotherapy BNT113 in HPV16‑positive head and neck squamous cell carcinoma. The study tests BNT113 in combination with che...

BioNTech Names KPMG as New Independent Auditor for 2027 Financial Year

Sep 18, 2026

BioNTech SE said on September 18, 2026, that its Supervisory Board has approved the appointment of KPMG AG Wirtschaftsprüfungsgesellschaft as the company’s independent auditor for the financial year ending December 31, 2027, pending shareholder appro...

BioNTech and OncoC4 Report Survival Gains for Gotistobart in Phase 3 Squamous NSCLC Trial

Sep 14, 2026

BioNTech SE and U.S.-based OncoC4, Inc., both active in oncology immunotherapy, are jointly developing gotistobart, an investigational CTLA-4-targeting monoclonal antibody designed to selectively deplete regulatory T cells in the tumour microenvironm...

BioNTech Halts Phase 2 mRNA Monotherapy Trial in Resected Colorectal Cancer After DSMB Review

Aug 28, 2026

On August 28, 2026, BioNTech SE announced it is terminating its Phase 2 BNT122-01 trial of autogene cevumeran, an individualized mRNA cancer immunotherapy, in ctDNA-positive, surgically resected high-risk Stage II and Stage III colorectal cancer pati...

BioNTech and Pfizer Secure FDA Nod for XFG-Adapted 2026–2027 COVID-19 Vaccine

Aug 27, 2026

Pfizer and BioNTech announced on August 27, 2026 that the U.S. Food and Drug Administration approved a supplemental Biologics License Application for their 2026‑2027 COMIRNATY XFG mRNA COVID‑19 vaccine, adapted to the XFG variant. The updated formula...

BioNTech to Unveil Novel Lung Cancer Combination Data at WCLC 2026

Aug 20, 2026

BioNTech SE reported on August 20, 2026, that it will present new clinical data from its lung cancer development program at the IASLC 2026 World Conference on Lung Cancer in Seoul from September 12‑15, 2026. The presentations center on late-stage ass...

BioNTech Deepens Investment in Oncology as Q2 Loss Widens and New CEO Named

Aug 4, 2026

On August 4, 2026, BioNTech reported second-quarter 2026 results showing revenues falling to €105.6 million, largely because of lower demand for its COVID-19 vaccines, while year-to-date revenues dropped to €223.7 million from €443.6 million a year e...

BioNTech Files Mid‑Year 2026 Interim Results and Development Update

Aug 4, 2026

On August 4, 2026, BioNTech SE reported unaudited financial results and a development update for the three and six months ended June 30, 2026, via a Form 6‑K filing with the U.S. Securities and Exchange Commission. The company disclosed interim conde...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026